⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Mitochondria-Targeted Esculetin (Mito-Esc)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-09-10 — Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.: Aged ApoE mouse study plus H9c2/primary cardiac fibroblast experiments: Mito-Esc attenuated cardiac hypertrophy, fibrosis, inflammation, and senescence via AMPK–SIRT1 activation and p38 MAPK inhibition, with effects reported comparable to metformin — preclinical only, no human data. [animal-model] (novelty: 3)
Open questions
Related
Contributing findings
Mitochondria-targeted esculetin mitigates age-associated cardiac remodeling through coordinated activation of AMPK-SIRT1 and inhibition of p38 MAPK signaling.
10-sep-2026
novelty 3
per-area 3
strengthens